Sanford C. Bernstein Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $310.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective decreased by Sanford C. Bernstein from $314.00 to $310.00 in a research report released on Tuesday morning,Benzinga reports. Sanford C. Bernstein currently has an outperform rating on the biopharmaceutical company’s stock.

Several other research analysts have also issued reports on the company. Chardan Capital restated a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Cantor Fitzgerald reissued a “neutral” rating and set a $220.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Bank of America upped their price target on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a report on Monday, October 14th. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. Finally, Needham & Company LLC restated a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty have given a buy rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $298.61.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $235.95 on Tuesday. The firm has a market capitalization of $30.43 billion, a PE ratio of -90.06 and a beta of 0.34. The stock’s fifty day moving average is $250.94 and its 200 day moving average is $259.67. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same quarter in the prior year, the company posted $1.15 earnings per share. The company’s revenue for the quarter was down 33.3% on a year-over-year basis. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -2.21 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the sale, the chief executive officer now owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the transaction, the chief marketing officer now owns 17,457 shares in the company, valued at $4,381,357.86. The trade was a 8.79 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,122 shares of company stock valued at $2,540,455. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC lifted its position in Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after acquiring an additional 135,829 shares during the period. Sanctuary Advisors LLC purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $578,000. Toronto Dominion Bank raised its stake in shares of Alnylam Pharmaceuticals by 27.3% in the third quarter. Toronto Dominion Bank now owns 15,466 shares of the biopharmaceutical company’s stock worth $4,254,000 after purchasing an additional 3,315 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Alnylam Pharmaceuticals by 22.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 73,320 shares of the biopharmaceutical company’s stock worth $20,165,000 after purchasing an additional 13,422 shares during the period. Finally, Parkman Healthcare Partners LLC purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $7,009,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.